A Preliminary Prospective Study Evaluating Efficacy And Safety Of Vildagliptin In Nonalcoholic Fatty Liver Disease (NAFLD) Patients With Type 2 Diabetes Mellitus

Trial Profile

A Preliminary Prospective Study Evaluating Efficacy And Safety Of Vildagliptin In Nonalcoholic Fatty Liver Disease (NAFLD) Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2016 New trial record
    • 19 Oct 2016 Status changed from active, no longer recruiting to completed, according to results presented at the 24th United European Gastroenterology Week.
    • 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top